Precigen to Engage in Virtual Fireside Chats Discussing Innovative Treatments

Precigen to Participate in Upcoming Virtual Fireside Chats

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company focused on innovative precision medicines, is set to engage in two virtual fireside chats. These discussions aim to shed light on their recently released FDA-approved treatment for adults with recurrent respiratory papillomatosis. This approval marks a significant milestone in the company's journey to enhance patient care through advanced therapeutic options.

Event Details

The first fireside chat will be hosted by Jennifer Kim, a biotech analyst from Cantor, on August 27, 2025, from 11 AM to 12 PM ET. Participants from Precigen will include the company's President and CEO Helen Sabzevari, PhD, and Chief Commercial Officer Phil Tennant. This event will provide invaluable insights into the therapeutic advancements and the implications of this new treatment for patients.

Following this, another virtual session will take place on September 2, 2025, moderated by Dr. Swayampakula Ramakanth, Managing Director of Equity Research at H.C. Wainwright. Similar to the earlier chat, Dr. Sabzevari and Mr. Tennant will discuss the specifics of the FDA's approval and its impact on patients and the biopharmaceutical landscape.

Joining the Webcast

Interested individuals can access the live webcasts of these events via Precigen's official website under the Events & Presentations section. This platform ensures comprehensive access to the discussions for investors, medical professionals, and the general public alike.

About Precigen

Founded with the mission to address challenging medical needs, Precigen is dedicated to developing innovative precision medicines. The company prioritizes creating therapeutic solutions that aim to solve complex and often untreated diseases. With a strong focus on immuno-oncology, infectious diseases, and autoimmune disorders, Precigen is committed to advancing scientific breakthroughs from proof-of-concept to commercial availability.

The recent approval of the treatment for recurrent respiratory papillomatosis emphasizes the company’s continuous efforts to push the boundaries of drug development. The therapy, now recognized by the FDA, represents a beacon of hope for many adults who suffer from this condition that has previously lacked adequate treatment options.

Conclusion

As Precigen gears up for these insightful discussions, it underscores the importance of innovation in healthcare. The virtual fireside chats not only aim to inform attendees about specific advancements but also to showcase the commitment of Precigen to improving patient outcomes through cutting-edge therapies. Whether you're a stakeholder in the biopharmaceutical industry, a healthcare professional, or just someone interested in the future of medicine, these upcoming events promise to deliver crucial knowledge and updates on recent advancements in treatment options.

For more information about Precigen and their journey towards precision medicine, please visit their official website at www.precigen.com.